These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 17455109)
1. Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Hanioka N; Tsuneto Y; Saito Y; Sumada T; Maekawa K; Saito K; Sawada J; Narimatsu S Xenobiotica; 2007 Apr; 37(4):342-55. PubMed ID: 17455109 [TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Hanioka N; Tsuneto Y; Saito Y; Maekawa K; Sawada J; Narimatsu S Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):388-93. PubMed ID: 18312490 [TBL] [Abstract][Full Text] [Related]
3. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260 [TBL] [Abstract][Full Text] [Related]
4. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147 [TBL] [Abstract][Full Text] [Related]
5. Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking. Oda A; Yamaotsu N; Hirono S Pharm Res; 2004 Dec; 21(12):2270-8. PubMed ID: 15648259 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. Wang H; An N; Wang H; Gao Y; Liu D; Bian T; Zhu J; Chen C Drug Metab Dispos; 2011 May; 39(5):830-7. PubMed ID: 21325430 [TBL] [Abstract][Full Text] [Related]
7. Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19. Niwa T; Kageyama A; Kishimoto K; Yabusaki Y; Ishibashi F; Katagiri M Drug Metab Dispos; 2002 Aug; 30(8):931-6. PubMed ID: 12124312 [TBL] [Abstract][Full Text] [Related]
8. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
9. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Lee SJ; Kim WY; Kim H; Shon JH; Lee SS; Shin JG Drug Metab Dispos; 2009 Nov; 37(11):2262-9. PubMed ID: 19661214 [TBL] [Abstract][Full Text] [Related]
10. In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24. Lau PS; Leong KV; Ong CE; Dong AN; Pan Y Biochem Genet; 2017 Feb; 55(1):48-62. PubMed ID: 27578295 [TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Blaisdell J; Mohrenweiser H; Jackson J; Ferguson S; Coulter S; Chanas B; Xi T; Ghanayem B; Goldstein JA Pharmacogenetics; 2002 Dec; 12(9):703-11. PubMed ID: 12464799 [TBL] [Abstract][Full Text] [Related]
13. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Mankowski DC Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802 [TBL] [Abstract][Full Text] [Related]
14. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777 [TBL] [Abstract][Full Text] [Related]
15. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554 [TBL] [Abstract][Full Text] [Related]
16. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism]. Lou YQ; Kuang TY Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218 [TBL] [Abstract][Full Text] [Related]
17. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262 [TBL] [Abstract][Full Text] [Related]
18. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680 [TBL] [Abstract][Full Text] [Related]
19. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Suzuki H; Kneller MB; Haining RL; Trager WF; Rettie AE Drug Metab Dispos; 2002 Mar; 30(3):235-9. PubMed ID: 11854139 [TBL] [Abstract][Full Text] [Related]
20. Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Saito K; Dan H; Masuda K; Katsu T; Hanioka N; Yamamoto S; Miyano K; Yamano S; Narimatsu S Chirality; 2007 Jul; 19(7):550-8. PubMed ID: 17487889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]